Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Open Access
- 1 February 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 2 (2), 234-240
- https://doi.org/10.1001/jamaoncol.2015.4368
Abstract
Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen 4 (CTLA-4) that induces antitumor immune responses by removing a key negative regulator of T cell activation. This antibody was the first agent to demonstrate improved overall survival for patients with advanced melanoma and received regulatory approval in 2011.1,2 Furthermore, durable benefits have been observed, with approximately 20% of patients surviving at least 5 years.3,4Keywords
This publication has 2 references indexed in Scilit:
- Faculty Opinions recommendation of Pembrolizumab versus Ipilimumab in Advanced Melanoma.Published by H1 Connect ,2016
- Faculty Opinions recommendation of Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant.Published by H1 Connect ,2016